Journals / Klinik Psikiyatri Dergisi / 2011 / Cilt: 14 - Sayı: 4

Diagnosis and treatment of premenstrual syndrome and premenstrual dysphoric disorder: A review

Premenstruel sendrom ve premenstruel disforik bozuklukta tanı ve tedavi: Bir gözden geçirme

Pages
241–253
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cognitive behavioral therapy may be an alternative psychosocial treatment to drug treatments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Premenstrual syndrome (PMS) is a condition which appear at the late luteal phase of menstrual cycles with physical changes include breast swelling, fatigue, headache, weight gain and psychological changes include depressive mood, irritability, and tension.
📊
Key Findings & Data:This syndrome can occur 80% of women population but it is severe form can only be seen 5% of women and called premenstrual dysphoric disorder or late luteal phase syndrome.
💡
Conclusion & Impact:Cognitive behavioral therapy may be an alternative psychosocial treatment to drug treatments.
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Premenstrual syndrome (PMS) is a condition which appear at the late luteal phase of menstrual cycles with physical changes include breast swelling, fatigue, headache, weight gain and psychological changes include depressive mood, irritability, and tension. These changes remit after the onset of menstruation. This syndrome can occur 80% of women population but it is severe form can only be seen 5% of women and called premenstrual dysphoric disorder or late luteal phase syndrome. In this review, current literature about diagnosis, etiology and treatment of premenstrual syndrome and premenstrual dysphoric disorder is examined. We searched Pubmed Medline (1950-2011)using the terms “premenstrual syndrome,” “premenstrual dysphoric syndrome,”. The exact cause of PMS has not been identified, but several theories were proposed to explain this disorder. Biological etiology of the disorder explained by the sensitivity of some women’s to normal biological fluctuations of gonadal hormones. Psychosocial factors also influence the severity of symptoms. These biological and psychological vulnerability presented as somatic and psychological symptoms of the premenstrual dysphoric disorder. Current evidences suggested that this disorders stem from the interaction between hormones and the central nervous system and pharmacological agents and psychosocial interventions can alleviate the symptoms of this disorder. For many women with mild symptoms, lifestyle approaches are enough to control symptoms. In severe cases, hormonal treatments and antidepressants may be helpful. Combined oral contraceptive drugs and selective serotonin-reuptake inhibitors are used to treat premenstrual symptoms. Cognitive behavioral therapy may be an alternative psychosocial treatment to drug treatments.

Özet

Premenstruel sendrom kadınlarda menstruel döngünün geç luteal döneminde memelerde şişkinlik, başağrısı, halsizlik ve kilo alımı gibi fiziksel ve depresif duygudurum, irritabilite, gerginlik gibi ruhsal belirtilerle kendini ortaya koyan bir tablodur. Bu tablo genellikle mensturasyonun başlamasıyla ortadan kalkar. Bu sendrom kadın popülasyonun % 80’inde görülmekle beraber yaklaşık %5 kadında klinik olarak anlamlı olacak şekilde şiddetlidir. Bu belirtilerin klinik veya sosyal olarak etkili olacak düzeyde olması durumunda Premensturel Disforik Bozukluk veya Geç Luteal Faz Bozukluğu adıyla bir psikiyatrik rahatsızlık olarak sınıflandırılması önerilmektedir. Bu gözden geçirme yazısında premenstruel sendrom ve premenstruel disforik bozukluğun tanı, etyoloji ve tedavisine ilişkin güncel literatür gözden geçirilmiştir. Rahatsızlığın biyolojik etyolojisi, her kadında görülen gonadal steroidlerdeki normal dalgalanmaya karşı bazı kadınların daha hassas olması ve bu hormonal etkilerin kendisini bedensel ve ruhsal belirtilerle ortaya koyması biçimindedir. Psikososyal etkenlerde belirtilerin şiddetini etkilemektedir. Güncel bulgular bu rahatsızlığın hormonal etkenlerle santral sinir sistemi arasındaki etkileşimden kaynaklandığını ve gerek farmakolojik gerekse de psikososyal yöntemlerin bu rahatsızlığın belirtilerini azaltabileceğini göstermektedir. Hafif vakalarda yaşam stili değişikliği yeterli olurken şiddetli vakalarda hormonal tedavi ve serotonin geri alım engelleyicileri kullanılmaktadır. Bu hastalarda ilaç tedavisine alternatif olarak bilişsel davranışçı terapide kullanılabilmektedir.

🔖

Cite This Article

TÜRKÇAPAR, A. F., TÜRKÇAPAR, M. H. (2011). Diagnosis and treatment of premenstrual syndrome and premenstrual dysphoric disorder: A review. Klinik Psikiyatri Dergisi, Cilt: 14 - Sayı: 4, 241–253. https://ajindex.com/articles/208889

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Adıgüzel H, Taşkın O, Danacı AE (2007) Manisa ilinde premenstrüel sendrom belirti örüntüsü ve belirti yaygınlığının araştırılması. Türk Psikiyatri Dergisi, 18(3):215-222.
  2. Akdeniz F, Aldemir E (2009) Kadınlara özgü ruhsal hastalıklar. Klinik Gelişim, 22:80-83.
  3. Altshuler LL, Victoria Hendrick V, Parry B (1995) Pharmacological management of premenstrual disorder Harvard Review of Psychiatry, 2:233-245.
  4. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4. Baskı (DSM-IV), Washington DC, American Psychiatric Assosiation. APA (2011) http://www.dsm5.org/proposedrevision/Pages/proposedrevision. aspx?rid=484 sitesinden 1.9.2011'de alınmıştır Bhatia SC, Bhatia SK (2002) Diagnosis and treatment of premenstrual dysphoric disorder. Am Fam Physician, 66:1239- 1248,1253-1254.
  5. Bloch M, Schmidt P, Rubinow D (1997) Premenstrual syndrome: evidence for symptom stability across cycles. Am J Psychiatry, 154: 1741-1746.
  6. Brown C, Ling F (2007) Hormonal therapies overview the premenstrual syndromes: PMS and PMDD. PM Shaughn O'Brien, AJ Rapkin, PJ Schmidt (Ed), Informa UK Ltd, London. Brown J, O' Brien PM, Marjoribanks J ve ark. (2009) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev, 15;(2):CD001396. Burt VK, Hendrick VC (2005) Clinical Manual of Women's Mental Health, American Psychiatric Publishing, Inc. Danacı AE, Taşkın EO, Kotlan SO ve ark. (2001) Premenstrüel disforik bozuklukta semptomatolojinin adet döngüsüyle ilişkisi. Anadolu Psikiyatri Dergisi, 2(1):15-20.
  7. Dereboy Ç, Dereboy F, Yiğitol F ve ark. (1994) Premenstrüel değerlendirme formunun psikometrik verileri: küme analitik bir çalışma. Türk Psikiyatri Dergisi 5:83-90.
  8. Freeman EW, Rickels K, Sondheimer SJ ve ark. (1999) Differential response to antidepressants in women with premenstrual syndrome premenstrual dysphoric disorder: A randomized controlled trial. Arch Gen Psychiatry, 56:932-939.
  9. Emans SJ, Laufer MR, Goldstein DP (2005) Premenstrual syndrome. Pediatric and Adolescent Gynecology, 5. baskı, Philadelphia, PA: Lippincott-Raven Inc, s.461-467.
  10. Endicott J (2000) History, evolution, and diagnosis of premenstrual dysphoric disorder. J Clin Psychiatry, 61:(Suppl 12):5-8.
  11. Endicott J, Harrison W, Neel J (2006) Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health, 9: 41-49.
  12. Epperson CN, Haga K, Mason GF ve ark. (2002) Cortical gamma-aminobutyric acid levels across the menstrual cycle in health